MobbleOpen in Mobble ⇢
Health · Drug development · published 2026-09-02 · via Drugs.com

Teva's Anti-IL-15 Antibody Shows Promise in Celiac Disease Trial

Teva reported positive topline data from a Phase 2a study of TEV-408, an anti-IL-15 antibody, for treating celiac disease. The company emphasized the potential of this approach as a pipeline-in-a-product opportunity.

Read the full article at Drugs.com →
Related stories
Novartis' remibrutinib shows positive Phase 3 results in relapsing MS · Drug development
Single-dose antibody reduces intestinal damage in celiac patients on gluten · Drug development
AstraZeneca's experimental heart failure pill yields mixed but encouraging phase 2 data · Drug development
Bispecific antibody meets survival goal in lung cancer study, Akeso reports · Cancer research
This summary is AI-generated and original to Mobble; the linked article is the authoritative source. Original headline: “Teva Announces Positive Topline Results from Phase 2a Study of TEV-408 in Celiac Disease.” Browse more stories.